Literature DB >> 80382

Significance of noncapsular antigens in protection against experimental Haemophilus influenzae type b disease: cross-reactivity.

R L Myerowitz, C W Norden, T A Demchak.   

Abstract

A bacterial strain, tentatively identified as an Actinobacillus species, was found to asymptomatically colonize the pharynx of some rats and to bear cell wall antigens which cross-react with noncapsular antigens of Haemophilus influenzae type b (HIb). The cross-reacting antigens appeared to be a heterogeneous mixture with varying molecular size and charge. The antigenic moieties are probably carbohydrate in nature. Antisera raised with this strain had both immunochemical and biological (bactericidal, opsonizing, and protective against experimental infection) activity against HIb. These findings lend further evidence to the idea that noncapsular antigens are important in the induction of resistance to HIb disease. The findings also raise the possibility of using bacteria which cross-react with noncapsular antigens for immunization against HIb disease in humans through nasopharyngeal or enteric colonization.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 80382      PMCID: PMC422038          DOI: 10.1128/iai.21.2.619-626.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Use of antiserum agar for detection of Haemophilus influenzae type b in the pharynx.

Authors:  R H Michaels; F E Stonebraker; J B Robbins
Journal:  Pediatr Res       Date:  1975-05       Impact factor: 3.756

2.  Experimental endogenous endophthalmitis caused by Haemophilus influenzae type b.

Authors:  R L Myerowitz; R Klaw; B L Johnson
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

3.  Countercurrent immunoelectrophoresis for the diagnosis of pneumococcal pneumonia in children.

Authors:  R H Michaels; C S Poziviak
Journal:  J Pediatr       Date:  1976-01       Impact factor: 4.406

4.  Potentiation of experimental meningitis due to Haemophilus influenzae by influenza A virus.

Authors:  R H Michaels; R L Myerowitz; R Klaw
Journal:  J Infect Dis       Date:  1977-04       Impact factor: 5.226

5.  Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3.

Authors:  J B Robbins; L Myerowitz; J K Whisnant; M Argaman; R Schneerson; Z T Handzel; E C Gotschlich
Journal:  Infect Immun       Date:  1972-11       Impact factor: 3.441

6.  Heteroimmunization to the capsular polysaccharide of Haemophilus influenzae type b induced by enteric cross-reacting bacteria.

Authors:  Z T Handzel; M Argaman; J C Parke; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

7.  Immunology of the infant rat experimental model of Haemophilus influenzae type b meningitis.

Authors:  R L Myerowitz; C W Norden
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

8.  Experimental Haemophilus influenzae type b meningitis: immunological investigation of the infant rat model.

Authors:  D M Granoff; R Rockwell
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

9.  Effect of neonatal gastrointestinal colonization with cross reacting Escherichia coli on anticapsular antibody production and bacteremia in experimental Haemophilus influenzae type b disease of rats.

Authors:  R L Myerowitz; C W Norden
Journal:  Infect Immun       Date:  1977-07       Impact factor: 3.441

10.  Human serum activities against Hemophilus influenzae, type b.

Authors:  P Anderson; R B Johnston; D H Smith
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

View more
  14 in total

1.  Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom.

Authors:  J McVernon; M E Ramsay; A R McLean
Journal:  Epidemiol Infect       Date:  2007-08-03       Impact factor: 2.451

2.  Identification of a 16,600-dalton outer membrane protein on nontypeable Haemophilus influenzae as a target for human serum bactericidal antibody.

Authors:  T F Murphy; L C Bartos; P A Rice; M B Nelson; K C Dudas; M A Apicella
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

3.  Mapping of bactericidal epitopes on the P2 porin protein of nontypeable Haemophilus influenzae.

Authors:  E M Haase; K Yi; G D Morse; T F Murphy
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

4.  Outer membrane protein composition in disease isolates of Haemophilus influenzae: pathogenic and epidemiological implications.

Authors:  M R Loeb; D H Smith
Journal:  Infect Immun       Date:  1980-12       Impact factor: 3.441

5.  Assessment of Haemophilus influenzae type b opsonins by neutrophil chemiluminescence.

Authors:  S L Kaplan; C L Umstead; E O Mason; D C Anderson; J C Parke; R D Feigin
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

6.  Human antibody response to individual outer membrane proteins of Haemophilus influenzae type b.

Authors:  M R Loeb; D H Smith
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

7.  Antibody response of infants to cell surface-exposed outer membrane proteins of Haemophilus influenzae type b after systemic Haemophilus disease.

Authors:  P A Gulig; G H McCracken; C F Frisch; K H Johnston; E J Hansen
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

8.  Antibodies to Haemophilus influenzae type b outer membrane proteins in children with epiglottitis or meningitis and in healthy controls.

Authors:  P D Johnson; S J MacInnes; G L Gilbert
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

9.  Generation of chemotactic activity in serum by Haemophilus influenzae type b.

Authors:  M F Tosi; S L Kaplan; E O Mason; G J Buffone; D C Anderson
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

10.  Bactericidal antibodies against noncapsular components of Haemophilus influenzae.

Authors:  T Dahlberg-Lagergård
Journal:  J Clin Microbiol       Date:  1983-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.